Boundless Bio Q2 net loss $15.7M; cash $127.1M funds operations into H1 2028

Boundless Bio, Inc.

2025-Q2 EPS reported -$1.41

Net loss $15.7M in Q2 2025 versus $17.0M in Q2 2024; R&D expenses fell to $12.2M from $14.7M.
Cash and investments $127.1M at June 30, 2025, supporting operations and proof-of-concept readouts into first half 2028.
BBI-355/BBI-825 combination arm of POTENTIATE trial open for enrollment; initial proof-of-concept data expected within cash runway.
BBI-940 (novel kinesin program) IND submission on track for first half 2026; clinical data anticipated within existing cash timeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.